Artivion, Inc. (AORT)
- Previous Close
23.50 - Open
23.73 - Bid 22.86 x 800
- Ask 23.98 x 900
- Day's Range
23.20 - 23.50 - 52 Week Range
12.16 - 25.51 - Volume
111,970 - Avg. Volume
210,500 - Market Cap (intraday)
979.089M - Beta (5Y Monthly) 1.66
- PE Ratio (TTM)
-- - EPS (TTM)
-0.24 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 9, 2015
- 1y Target Est
26.75
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
artivion.comRecent News: AORT
Performance Overview: AORT
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AORT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AORT
Valuation Measures
Market Cap
979.09M
Enterprise Value
1.29B
Trailing P/E
--
Forward P/E
166.67
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.71
Price/Book (mrq)
3.32
Enterprise Value/Revenue
3.51
Enterprise Value/EBITDA
25.61
Financial Highlights
Profitability and Income Statement
Profit Margin
-2.61%
Return on Assets (ttm)
1.78%
Return on Equity (ttm)
-3.35%
Revenue (ttm)
368.21M
Net Income Avi to Common (ttm)
-9.58M
Diluted EPS (ttm)
-0.24
Balance Sheet and Cash Flow
Total Cash (mrq)
51.12M
Total Debt/Equity (mrq)
123.13%
Levered Free Cash Flow (ttm)
8.98M
Research Analysis: AORT
Company Insights: AORT
AORT does not have Company Insights